ZOMETA ® helps to protect patients like Marta from the threat of SREs
- The threat of an SRE doesn't end at 6 months4,5
- Half of patients with untreated bone metastases from breast cancer will experience an SRE within 1 year4
Efficacy of ZOMETA vs placebo in a Japanese study of patients
with breast cancer and bone metastases: median time to first SRE4
- ZOMETA significantly extended time to first SRE vs placebo (median not reached
vs 364 days, respectively; P=.007)4
- ZOMETA reduced the relative risk of SREs vs placebo by 40%4
- ZOMETA demonstrated efficacy equivalent to pamidronate in delaying median time to first SRE in an additional noninferiority trial in patients with breast cancer or multiple myeloma7
ZOMETA can delay and reduce SREs in patients like Marta with breast cancer and bone metastases4,7
